SLNO · Soleno Therapeutics Inc
$53.01
+0.00 (+0.00%)
At close · May 18
Market Cap
$2.76B
Shares
52.12M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$53.01
Open$53.01
Day$53.01–53.01
52W$29.43–90.32
Avg vol 30d3.3M
Short int4.4M · 8.5% float · 2.3d
Short vol31%
Last earningsFeb 25, 2026
DataJan 2020–May 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+1%
above
Price vs 50-day avg
+16%
above
RSI (14)
78
overbought
MACD trend
Negative
52-week position
39%
mid-range
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+18%
trailing
YTD return
+14%
this year
Relative strength
+5%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $46 › 200d $52 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +43 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.45% of float · ▼ -32.5% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
227 holders — mid 3-yr range
Fundamentals
Revenue growth
+139%
Y/Y
Gross margin
-4%
contracting
EPS growth
+109%
Y/Y
Free cash flow
$46.7M
Valuation
P/E 27.5
in line
Balance sheet
$20.2M
net cash
Quant / Vol
risk profile
Volatility
69%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
0.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+1%
Bullish
Price vs 50-day avg
+16%
Bullish
RSI (14)
78
Bearish
MACD trend
Negative
Bearish
52-week position
39%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $46 › 200d $52 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +43 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
8.45% of float · ▼ -32.5% MoM · 2.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
227 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $29
Now $53 · 39%
52-wk high $90
vs 200-day avg +1%
vs 50-day avg +16%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| active patients on drug | 859 | as of December 31, 2025 | — |
| cash flow from operating activities | $48.7M | the fourth quarter | — |
| invested in accelerated share repurchase program | $100M | the year ended December 31, 2025 | — |
| lives covered | 185M | from approval on March 26, 2025 through December 31, 2025 | — |
| new prescribers in the fourth quarter | 136 | the fourth quarter | — |
| patient start forms received | 1,250 | from approval on March 26, 2025 through December 31, 2025 | — |
| patient start forms received (fourth quarter) | 207 | the fourth quarter | — |
| unique prescribers | 630 | from approval on March 26, 2025 through December 31, 2025 | — |
| Discontinuation rate of VYKAT XR related to adverse events | 12% | fourth quarter 2025 | — |
| Lives covered as percentage of total lives | 60% | from launch through December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SLNO
this stock
Soleno Therapeutics Inc
|
$2.76B | +14.5% | +138.8% | 27.5 | 8.5% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SLNO | +0.1% | +0.7% | +17.5% | +0.4% | +14.5% |
| SPY | -0.1% | +4.4% | +12.1% | +2.8% | +8.3% |
| vs SPY | +0.2% | -3.7% | +5.4% | -2.5% | +6.2% |